Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
ABL Bio
company
About
It is based on developing bispecific antibody cancer programs.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- ₩20B
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
ABL Bio is one of the world's leading biotech research companies focusing on the development of therapeutic drugs for immuno-oncology & neurodegenerative diseases. Their core values are life-improvement, collaboration, innovation and novel therapy.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
₩29B
ABL Bio has raised a total of
₩29B
in funding over 2 rounds. Their latest funding was raised on
Mar 31, 2017 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Mar 31, 2017 | Series B | ₩20B | 2 | — | — | Detail |
| Jul 19, 2016 | Series A | ₩9B | 1 |
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
3
ABL Bio is funded by 3 investors.
HantuPa
and Global Bio Growth First Private Equity Investment
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
Yes | Series A |
|
|
— | Series B |
|
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
